Unichem Labs to step up API production
"Over-dependence of the Indian pharmaceutical industry on imported APIs exposes it to raw material supply disruptions and pricing volatility," Mody said.;
New Delhi: Drug firm Unichem Laboratories has called for measures to step up local production of raw materials to produce drugs in order to reduce the country''s dependence on imports, especially from China.
Sharing information with shareholders in company''s annual report for 2019-20, the drug firm said the ongoing coronavirus pandemic calls for concentrated efforts to build upon capacities for active pharmaceutical ingredients (APIs) in the country.
"Our country is heavily dependent on China for import of most of its APIs. India needs a healthy and financially strong ecosystem to boost the manufacture of APIs to remain self-reliant in the years to come," Unichem Laboratories Chairman and Managing Director Prakash A Mody said.
The present health crisis calls for proactive measures to step up economies of scale in the production of intermediates and other key materials, with focus on research and development for APIs, he added.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.